The need for escalation or de-escalation has to be checked on a regular basis. In addition to the pharmacological treatment, moderate physical training is a mainstay of the treatment and has been shown to improve muscle weakness in myositis [35]. In case of extramuscular manifestation, interdisciplinary individual care is essential. refractory myositis. IVIG, an antibody therapy in the wider sense, has now been licensed for DM following a recent positive clinical trial. Negative study results were reported in randomized trials with infliximab, sifalimumab and bimagrumab. Studies on basiliximab and Ombrabulin hydrochloride eculizumab are currently underway, and are expected to yield results in a couple of years. Despite some encouraging results of clinical studies with antibody therapy in myositis, further research is crucial to optimize the treatment for this debilitating disease and to find treatment alternatives for treatment-refractory patients. == Supplementary Information == The online version contains supplementary material available at 10.1007/s13311-022-01220-z. Keywords:Myositis, Treatment, Inflammatory myopathies, Antibodies, Clinical trial, Rituximab == Introduction == Inflammatory myopathies, generally called myositis, are a group of heterogeneous diseases including the subtypes dermatomyositis (DM), juvenile dermatomyositis (JDM), polymyositis (PM), necrotizing myopathy (NM), antisynthetase syndrome (ASS), overlap myositis (OM) and inclusion body myositis (IBM). The myositis subtypes are all rare diseases. The incidence ranges from 2 to 5 cases per million in 1 year. Whereas IBM affects more men than women and occurs in the older age, the other subtypes more commonly impact middle-aged women [1]. JDM also occurs more in ladies; the mean age of manifestation is around 6.7 years in girls and 7.3 years in boys [2]. The most recent Ombrabulin hydrochloride classification Ombrabulin hydrochloride for myositis is the 2017 EULAR/ACR criteria for adult and juvenile idiopathic inflammatory myopathies, which use clinical, serological and histological parameters to identify the most common myositis subtypes DM, JDM, PM and IBM [3]. The common symptom in all myositis subtypes is usually subacute or chronic muscle weakness caused by autoimmune damage of the muscle tissue, resulting in physical disability. Additional common clinical findings in DM and JDM are skin lesions and calcinosis, which can be the leading symptoms. Patients can suffer from interstitial lung disease and arthralgia, especially with an ASS. Besides the involvement of lungs and joints, all myositis subtypes can show further extramuscular manifestations of the myocardium and kidney, as well as dysphagia due to involvement of the pharyngeal muscle tissue [4]. Laboratory assessments usually show an increase of creatine kinase, and frequently the presence of myositis-specific and/or myositis-associated autoantibodies. They can aid in differentiating the subtypes and estimating the risk for extramuscular involvement and neoplasia [4]. For instance, patients with anti-MDA5 antibodies are at higher risk for severe lung involvement [5], whereas the occurrence of anti-TIF1- and anti-NXP2 antibodies is usually highly associated with malignancy [6]. A further important diagnostic tool is usually a muscle mass biopsy with comprehensive histological evaluation. Muscle mass biopsies show characteristic histopathological patterns of inflammatory mechanisms. In DM, the muscle mass biopsy shows match activation and intravascular deposition of the membrane attack complexes (MAC), which lead to capillary destruction, necrosis of muscle tissue fibres and perivascular inflammation with CD4+ T-cells [7,8]. In PM and IBM, CD8+ T-cells dominating the infiltrate and MHC-I upregulation on muscle mass fibres are common findings. Moreover, IBM is usually characterized by inclusion body consisting of amyloid and other degenerative protein aggregates [9]. So far, the aetiology of myositis is usually complex and not completely comprehended. Similar to other autoimmune diseases, the development of myositis is usually assumed to result from an conversation of various factors. On the one hand, genetic risk factors such as the HLA 8.1 ancestral haplotype and other genetic variants have been identified [10,11]. Additionally, a variety of Ombrabulin hydrochloride environmental factors have been proposed to be associated with an increased risk of myositis, possibly acting on top of genetic susceptibility. These include certain viral or bacterial infections, smoking, medications and ultraviolet radiation, although evidence is mainly based upon animal models, case reports or case series [12]. The disease mechanisms that lead to muscle mass inflammation and damage involve the innate immune system, including cytokines and chemokines, as well as the adaptive immune system, including the specific B- and Itga9 T-cell response. In addition, there is growing evidence of the importance of non-immune-mediated factors, such as cell stress and mitochondrial damage, as well as impaired autophagy [12]. In order to develop possible targets for therapies in myositis, research interest focuses on the various pathomechanisms and Ombrabulin hydrochloride molecular key players in myositis. Due to increasing understanding of the pathogenesis in the different subtypes of myositis, new specific targets have been discovered and an individualized therapy becomes more feasible. The following sections summarize the evidence existing for antibody therapy in myositis, from well-established brokers to new methods and targeted therapies in.